Safety of triptans for migraine headaches during pregnancy and breastfeeding.

Abstract

QUESTION:

A patient who just found out that she is pregnant and suffers from migraine headaches informs me that she has been taking naratriptan. She indicates that she is planning on breastfeeding her baby and might need to continue treatment. How safe are the medications from this class of drugs during pregnancy and breastfeeding?

ANSWER:

Accumulated data suggest that exposure to sumatriptan during pregnancy does not increase the risk of birth defects above the baseline rate. There are currently insufficient data to confirm the safety of other triptans; however, evidence to date is reassuring. Information regarding safety of triptans while breastfeeding is limited but also reassuring, as the minimal amounts excreted into the milk are insufficient to cause any adverse effects on the breastfeeding infant.

• Authors: Silvia Duong, Pina Bozzo, Hedvig Nordeng, Adrienne Einarson
• Journal: Canadian family physician Medecin de famille canadien (Can Fam Physician) Vol. 56 Issue 6 Pg. 537-9 (Jun 2010) ISSN: 1715-5258 [Electronic] Canada
• PMID: 20547518 (Publication Type: Journal Article)

Chemical References

• Piperidines
• Serotonin 5-HT1 Receptor Agonists
• Tryptamines
• Sumatriptan
• naratriptan

Topics

• Breast Feeding
• Female
• Humans
• Migraine Disorders (drug therapy)
• Piperidines (adverse effects, therapeutic use)
• Pregnancy
• Pregnancy Complications (drug therapy)
• Pregnancy Outcome
• Risk Factors
• Serotonin 5-HT1 Receptor Agonists (adverse effects, therapeutic use)
• Sumatriptan (adverse effects, therapeutic use)
• Tryptamines (adverse effects, therapeutic use)